Cellectis S.A.
ALCLS.PA · PAR
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.00 | -0.05 | 0.29 |
| FCF Yield | -7.02% | -13.51% | -1.18% | -3.42% |
| EV / EBITDA | -11.17 | -8.34 | 7.05 | -7.68 |
| Quality | ||||
| ROIC | -4.81% | -6.61% | -4.26% | -4.40% |
| Gross Margin | 85.50% | 81.09% | 100.00% | 100.00% |
| Cash Conversion Ratio | -2.67 | 0.43 | 0.95 | -0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 65.86% | 50.37% | 39.02% | 29.11% |
| Free Cash Flow Growth | 39.53% | -879.63% | 72.99% | -112.97% |
| Safety | ||||
| Net Debt / EBITDA | -2.10 | 3.18 | -3.65 | 4.10 |
| Interest Coverage | -4.67 | -7.42 | -5.60 | -5.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -492.26 | -553.07 | 163.04 | 154.87 |